John J Dillon

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. pmc Rituximab therapy in idiopathic membranous nephropathy: a 2-year study
    Fernando C Fervenza
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Clin J Am Soc Nephrol 5:2188-98. 2010
  2. ncbi request reprint Rituximab therapy for Type I membranoproliferative glomerulonephritis
    John J Dillon
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
    Clin Nephrol 77:290-5. 2012
  3. ncbi request reprint Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy
    John J Dillon
    Division of Nephrology, Mayo Clinic and Foundation, 200 1st Street, NW, Rochester, MN 55905, USA
    Semin Nephrol 24:218-24. 2004
  4. pmc Use of sevelamer hydrochloride as an oxalate binder
    John C Lieske
    Mayo Clinic Division of Nephrology and Hypertension and Mayo Hyperoxaluria Center, Rochester, Minnesota 55905, USA
    J Urol 179:1407-10. 2008
  5. pmc Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study
    Maria V Irazabal
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN, USA
    Nephrol Dial Transplant 28:137-46. 2013

Collaborators

Detail Information

Publications5

  1. pmc Rituximab therapy in idiopathic membranous nephropathy: a 2-year study
    Fernando C Fervenza
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55901, USA
    Clin J Am Soc Nephrol 5:2188-98. 2010
    ..This hypothesis was supported by previous pharmacokinetic (PK) analysis showing that RTX levels in the two-dose regimen were 50% lower compared with nonproteinuric patients, which could potentially result in undertreatment...
  2. ncbi request reprint Rituximab therapy for Type I membranoproliferative glomerulonephritis
    John J Dillon
    Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA
    Clin Nephrol 77:290-5. 2012
    ..It has no established treatment in adults. Our hypothesis was that this disease would respond to B cell depletion with rituximab, an anti-CD20 monoclonal antibody...
  3. ncbi request reprint Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy
    John J Dillon
    Division of Nephrology, Mayo Clinic and Foundation, 200 1st Street, NW, Rochester, MN 55905, USA
    Semin Nephrol 24:218-24. 2004
    ..However, the D allele of the ID polymorphism, particularly the DD genotype, could predict a favorable response to renin-angiotensin blockade...
  4. pmc Use of sevelamer hydrochloride as an oxalate binder
    John C Lieske
    Mayo Clinic Division of Nephrology and Hypertension and Mayo Hyperoxaluria Center, Rochester, Minnesota 55905, USA
    J Urol 179:1407-10. 2008
    ..A secondary objective was to assess changes in the urinary excretion of other substances associated with nephrolithiasis...
  5. pmc Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study
    Maria V Irazabal
    Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN, USA
    Nephrol Dial Transplant 28:137-46. 2013
    ..Selective urinary biomarkers have been considered superior to total proteinuria in predicting response to treatment and outcome in patients with membranous nephropathy (MN)...